2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 240

Longitudinal Femorotibial Cartilage Thickness Increase In Young Athletes At The End Of Adolescence
Abstract Number: 906

Longitudinal Patterns Of Depression In Lupus
Abstract Number: 1966

Longitudinal Quantification Of Bone Erosions In Patients With Rheumatoid Arthritis Using High-Resolution Computed Tomography
Abstract Number: 2128

Longitudinal Relation Of Sensitization To Incident Knee Pain, Incident Symptomatic Knee Osteoarthritis and Increase In Pain Severity: The Multicenter Osteoarthritis Study
Abstract Number: 2891

Loss Of Caspase 8 Exacerbates Dendritic Cell Activation In a MyD88- and RIPK1-Dependent Manner That Is Controlled By Inhibitory Molecules Transcribed By IRF3
Abstract Number: 1308

Low Accuracy Of Radiograph Reports In Identifying Patients With Rheumatoid Arthritis In The Veterans Affairs Rheumatoid Arthritis Registry
Abstract Number: 1244

Low Bone Mineral Density In African-American Males May Be More Prevalent Than Previously Reported and Exhibits Association With Low BMI But Not Older Age – Results Of a Retrospective Cohort Analysis
Abstract Number: 779

Low Cardiovascular Mortality Among Early Rheumatoid Arthritis Patients — A Nationwide Register Study 2000—2008
Abstract Number: 597

Low Complement (C3), Male Gender and Methotrexate Use Are Associated With Noncalcified Plaque In Systemic Lupus Erythematosus
Abstract Number: 819

Low Diagnostic Utility Of Candidate Definitions For a Positive MRI Of The Spine In Axial Spondyloarthritis
Abstract Number: 1092

Low Dose Naltrexone In The Treatment Of Fibromyalgia
Abstract Number: 2390

Low Dose Of Tocilizumab Can Be Effective In RA Patients Who Achieve Remission.
Abstract Number: 1758

Low Literacy Decision Aid Enhances Knowledge and Reduces Decisional Conflict Among Diverse Population Of Adults With Rheumatoid Arthritis: Results Of a Pilot Trial
Abstract Number: 2630

Low Medication Adherence Is Observed In Behcet’s Disease
Abstract Number: 2806

Low Risk Of Hepatitis B Virus Surface Antigen Seroreversion In HBsAg Negative/Anti-Hbc Positive Carriers Undergoing Rituximab For Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].